(Reuters) – Biogen’s shares rose 2% on Monday as a unanimous backing of its Alzheimer’s drug by the U.S. health regulator’s advisers strengthened the case for a traditional app[...]
Read more
Health
Swiss regulator welcomes UBS’s strategic focus
ZURICH (Reuters) – Swiss financial regulator FINMA has specified the central elements of its regulatory requirements for the merged UBS and Credit Suisse, it said on Monday. The regulator also s[...]
Read more
Novo Nordisk invests $2.3 billion in Danish production facility
COPENHAGEN (Reuters) -Danish drugmaker Novo Nordisk will invest 15.9 billion Danish crowns ($2.29 billion) to expand a production facility in Denmark for products to treat serious chronic diseases, th[...]
Read more
BioNTech faces first German lawsuit over alleged COVID vaccine side effects
By Ludwig Burger and Patricia Weiss HAMBURG (Reuters) -BioNTech will go to court on Monday to defend itself against a lawsuit from a German woman who is seeking damages for alleged side effects of its[...]
Read more
US judge rejects 3M effort to resolve earplug lawsuits in bankruptcy
By Dietrich Knauth NEW YORK (Reuters) -A U.S. judge on Friday dismissed the bankruptcy of 3M subsidiary Aearo Technologies, rejecting an effort to resolve nearly 260,000 lawsuits alleging that 3M mili[...]
Read more
AstraZeneca signs $2 billion agreement with Quell to develop cell therapies
(Reuters) – AstraZeneca said on Friday it had signed an agreement with Quell Therapeutics potentially worth more than $2 billion to develop cell therapies that could cure autoimmune diseases. Th[...]
Read more
Novartis’ Sandoz wagers its standalone future on biosimilar success
By Natalie Grover LONDON (Reuters) – Novartis’ soon-to-be spun off generics division Sandoz is betting on biosimilars, copies of high-priced drugs used to treat illnesses such as rheumatoi[...]
Read more
Teva to pay Nevada $193 million over role in opioid epidemic
By Brendan Pierson (Reuters) – Teva Pharmaceutical Industries on Wednesday agreed to pay Nevada $193 million to settle claims that its marketing practices fueled opioid addiction, the state anno[...]
Read more
CEO of Germany’s Merck: decoupling from China would be at huge economic cost
By Ludwig Burger and Patricia Weiss FRANKFURT (Reuters) -The CEO of German technology group Merck KGaA said that unravelling trade ties with China would come at great economic cost and she was banking[...]
Read more